PMCB News and Press, PharmaCyte Biotech Inc. From 09/09/21

Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations Cardiff Oncology ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting off the day with a dive into the biggest pre-market stock movers for Thursday. Source: ventdusud / Shutterstock.com There’s a lot of reason for stocks to be moving ...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it will be presenting at the ...

There's no denying that PharmaCyte Biotech (PMCB) stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence. Cheap stocks can be fun and profitable to trade, as long as you're careful. Today I'd like to feature PharmaCyte Biotech &l...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that its clinical trial product, CypCaps™, remains ...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the Company will expand its p...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the closing of its previously anno...

I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold. Historically, the company (or its investors) has proved to be quite expert in self-promotion. Your entry price per share should be at...

Gainers: Sonnet BioTherapeutics (NASDAQ:SONN) +127%. Sonoma Pharmaceuticals (NASDAQ:SNOA) +90%. DLocal (NASDAQ:DLO) +26%. Ensysce Biosciences (NASDAQ:ENSC) +23%. Macy's (NYSE:M) +22%. NLS Pharmaceutics (NASDAQ:NLSP) +21%. China Liberal Education (NASDAQ:CLEU) +19%. AudioEye (NASDAQ:AEYE) +14%...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it has entered into definitiv...